Thus, we first asked if MAL3-101 sensitive and resistant breast cancer cells exhibited unique sensitivities to the mTOR inhibitor, everolimus (also known as Afinitor), an FDA-approved rapamycin derivative that directly inhibits mTORC1 and indirectly inhibits mTORC2 (Chen and Zhou, 2020; Chiang and Abraham, 2007; Meng and Zheng, 2015). Here, MTOR is linked to breast carcinoma.